As of 2025-12-25, the Intrinsic Value of Sarepta Therapeutics Inc (SRPT) is 27.86 USD. This SRPT valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 22.32 USD, the upside of Sarepta Therapeutics Inc is 24.80%.
The range of the Intrinsic Value is 19.73 - 45.79 USD
Based on its market price of 22.32 USD and our intrinsic valuation, Sarepta Therapeutics Inc (SRPT) is undervalued by 24.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 19.73 - 45.79 | 27.86 | 24.8% |
| DCF (Growth 10y) | 21.34 - 44.96 | 28.81 | 29.1% |
| DCF (EBITDA 5y) | 46.27 - 60.45 | 52.89 | 137.0% |
| DCF (EBITDA 10y) | 43.54 - 62.52 | 52.09 | 133.4% |
| Fair Value | -64.78 - -64.78 | -64.78 | -390.21% |
| P/E | (35.39) - 44.38 | 1.32 | -94.1% |
| EV/EBITDA | (7.67) - 149.88 | 48.80 | 118.6% |
| EPV | (25.55) - (34.53) | (30.04) | -234.6% |
| DDM - Stable | (16.89) - (40.67) | (28.78) | -228.9% |
| DDM - Multi | 19.40 - 36.76 | 25.44 | 14.0% |
| Market Cap (mil) | 2,338.91 |
| Beta | 1.29 |
| Outstanding shares (mil) | 104.79 |
| Enterprise Value (mil) | 2,760.98 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.24% |
| Cost of Debt | 5.50% |
| WACC | 8.59% |